|
Jun 21
|
Uniqure Crashes To Six-Year Low On Muddy Results For Huntington's Gene Therapy
|
|
Jun 21
|
Why uniQure Stock Is Crashing Today
|
|
Jun 21
|
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
|
|
Jun 20
|
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
|
|
Jun 20
|
CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B
|
|
May 2
|
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
|
|
May 2
|
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|